How big is CytoSorbents Corp.?

As of Jun 18, CytoSorbents Corp. has a market capitalization of 75.13 million, with net sales of 34.53 million and a net profit of -15.83 million over the last four quarters. The company's shareholder's funds are 11.11 million, and total assets amount to 50.96 million.

Market Cap: As of Jun 18, CytoSorbents Corp. has a market capitalization of 75.13 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, CytoSorbents Corp. reported net sales of 34.53 million and a net profit of -15.83 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 11.11 million, while total assets were reported at 50.96 million.

What does CytoSorbents Corp. do?

CytoSorbents Corporation is a micro-cap immunotherapy company specializing in blood purification technology, specifically its product CytoSorb. As of March 2025, it reported net sales of $9 million and a market cap of $75.13 million.

Overview: <BR>CytoSorbents Corporation is a critical care focused immunotherapy company engaged in commercializing its blood purification technology, CytoSorb, within the Pharmaceuticals & Biotechnology industry and operates in the micro-cap market.<BR><BR>Financial Snapshot: <BR>Net Sales: 9 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 75.13 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 0.23 <BR>Return on Equity: -107.06% <BR>Price to Book: 5.17<BR><BR>Contact Details: <BR>Address: 7 Deerpark Dr Ste K, MONMOUTH JUNCTION NJ: 08852-1977 <BR>Website: http://cytosorbents.com/

Should I buy, sell or hold CytoSorbents Corp.?

Who are in the management team of CytoSorbents Corp.?

As of March 2022, the management team of CytoSorbents Corp. includes Al Kraus (Independent Non-Executive Chairman), Phillip Chan (President and CEO), and independent directors Michael Bator, Edward Jones, and Alan Sobel. This team provides governance and strategic direction for the company.

As of March 2022, the management team of CytoSorbents Corp. includes the following individuals:<BR><BR>- Mr. Al Kraus, who serves as the Independent Non-Executive Chairman of the Board.<BR>- Mr. Phillip Chan, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Michael Bator, who is an Independent Director.<BR>- Dr. Edward Jones, who is also an Independent Director.<BR>- Mr. Alan Sobel, who serves as an Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is CytoSorbents Corp. technically bullish or bearish?

As of September 11, 2025, CytoSorbents Corp. is in a mildly bearish trend, indicated by negative signals from the MACD, Bollinger Bands, and KST, and has significantly underperformed the S&P 500 with a 1-year return of -34.30% compared to the S&P's 17.14%.

As of 11 September 2025, the technical trend for CytoSorbents Corp. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by bearish signals in the weekly MACD, Bollinger Bands, and KST, alongside a bearish daily moving average. The weekly Dow Theory also indicates a mildly bearish trend. <BR><BR>In terms of performance, the stock has underperformed compared to the S&P 500 across multiple time frames, with a 1-year return of -34.30% versus the S&P 500's 17.14%, and a 5-year return of -89.24% compared to the S&P's 96.61%.